Chime Biologics logo — Sound Solution for Manufacturing

Chime Biologics

Sound Solution for Manufacturing

Founded 2013 China Shanghai, China 25 employees Series A Total: $207.40M Biopharma, Biotechnology +3

General Information

Company Name Chime Biologics
Founded Year 2013
Location China Shanghai, China
Founders / Decision Makers
Team member
Employees 25
Industries Biopharma, Biotechnology, Health Care +2
Funding Stage Series A
Business Model B2B, White Label, B2B2B
Revenue Model Service Fee, Project Based
Social

BounceWatch is an independent company data service, not affiliated with Chime Biologics. To contact Chime Biologics, visit chimebiologics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Chime Biologics compare?

A PDF of Chime Biologics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Chime Biologics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Chime Biologics

Chime Biologics is a well-established Contract Development and Manufacturing Organization (CDMO) with a focus on providing cost-effective and customer-centric biopharmaceutical development and manufacturing solutions. Founded in 2013, the company supports clients through every phase of drug development, from initial analytical and process transfer to late-stage commercial manufacturing.

The company's operations are headquartered in China, serving a global market with premier-quality biopharmaceutical products. In the competitive landscape of Biopharma, Biotechnology, Health Care, Manufacturing, and Pharmaceutical industries, Chime Biologics distinguishes itself by offering comprehensive solutions for Global Supply.

Recently, Chime Biologics secured a Series A investment from Wuhan Optics Valley Financial Holding Group as of 01 December 2025, reflecting strong investor confidence in its capabilities and growth potential.

Business keywords: Contract Development and Manufacturing Organization, CDMO, Biopharmaceutical Development, Biopharmaceutical Manufacturing, Customer-Centric Services, Cost-Effective Solutions, Analytical Services, Process Transfer, Early-Stage Development, Late-Stage Clinical Manufacturing, Commercial Drug Manufacturing, Global Supply, Process Validation, Technology Transfer, Single Use Bioreactors

Services & Products

End-to-end CDMO services
Cell Line Development
Process Development
Protein Science Characterization
Technology Transfer
Drug Substance Manufacturing
Drug Product Manufacturing
Quality Control and Assurance

Target Customers

Biotech companies Pharmaceutical companies Research organizations focused on biologics

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series A Undisclosed 1
Wuhan Optics Valley Financial Holding Group
01 Dec 2025
Series A $17.40M 1
Panacea Venture
01 Feb 2023
Series A $65.00M 3
Panacea Venture, VMS Group +1
01 Mar 2021
Series A $125.00M -
01 Feb 2020

Chime Biologics Alternatives & Competitors

View All Alternatives
Chime Biologics vs

Your full-service CDMO for viral vaccines, cell & gene therapeutics and other biologics protecting h...

502 employees
Health Care, Manufacturing
Chime Biologics vs

Your premier CDMO for biologics drug development and manufacturing, from early development, to IND,...

Series B
73 employees
Biopharma, Biotechnology
Chime Biologics vs

Multi-Service Pharmaceutical Contract Development Manufacturing Organization (CDMO)

Venture round
20 employees
Biotechnology, Pharmaceutical

FAQ About Chime Biologics

Sound Solution for Manufacturing
Chime Biologics was founded in 2013.
Chime Biologics is headquartered in Shanghai, China.
Chime Biologics operates in Biopharma, Biotechnology, Health Care, Manufacturing and Pharmaceutical. Its work centres on Contract Development and Manufacturing Organization, CDMO, Biopharmaceutical Development and Biopharmaceutical Manufacturing. Its customers include Biotech companies, Pharmaceutical companies and Research organizations focused on biologics.
Chime Biologics has a B2B, White Label and B2B2B business model. Its revenue comes from Service Fee and Project Based.
Chime Biologics has approximately 25 employees.
Chime Biologics has completed 4 funding rounds, raising a total of $207.40M. The latest funding stage is Series A.
Chime Biologics offers: End-to-end CDMO services, Cell Line Development, Process Development, Protein Science Characterization, Technology Transfer, Drug Substance Manufacturing, Drug Product Manufacturing, Quality Control and Assurance, Regulatory Support, Material Management & Logistics.
Top alternatives and competitors to Chime Biologics include IDT Biologika, JOINN Biologics US Inc., CritiTech Particle Engineering Solutions, CMAB Biopharma, Groupe PARIMA. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Chime Biologics and IDT Biologika are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Chime Biologics, https://bouncewatch.com/company/chime-biologics, updated 15 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes